Drug intelligence / Profile preview

CKD-701

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal, Ophthalmic

Overview

CKD-701 is a ranibizumab biosimilar developed by Chong Kun Dang Pharmaceutical. It is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), which is responsible for the excessive formation of blood vessels in the retina. Phase III clinical trials have demonstrated that CKD-701 has comparable clinical efficacy, safety, and immunogenicity to the reference ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration (nAMD).

Other names: Ranibizumab biosimilar

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on CKD-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-701.

Explore the full profile